Meeting
2022 ASCO Annual Meeting
Efficacy of afatinib in patients with advanced/metastatic solid tumors harboring NRG1 gene fusions: A novel, prospective real-world outcomes study based on single-patient protocol data.
Authors
Stephen V. Liu
Georgetown University Medical Center, Washington, DC
Stephen V. Liu , Lori Ann E. Minasi , Matthias Herpers , Claas Frohn
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Tissue-Based Biomarkers
Clinical Trial Registration Number
NCT05107193
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr TPS3180)
DOI
10.1200/JCO.2022.40.16_suppl.TPS3180
Abstract #
TPS3180
Poster Bd #
157a
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
The genomic landscape of gene fusions across solid tumors and clinical outcome of targeted therapies: A real-world retrospective analysis.
First Author: Yumeng Zhang
Poster
2020 ASCO Virtual Scientific Program
Characterization of NRG1 gene fusion events in solid tumors.
First Author: Sushma Jonna
First Author: Stephen V. Liu
Poster
2024 ASCO Annual Meeting
A multicohort platform trial to improve drug access for pediatric cancer patients in Japan: The PARTNER trial (NCCH2220).
First Author: Bunpei Miyazaki